Betta Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative medicines, with a particular emphasis on precision oncology. Founded in 2003 and headquartered in Hangzhou, the company has built an integrated platform spanning drug discovery, clinical development, manufacturing, and commercialization, with a pipeline encompassing both small-molecule therapies and biologics.

Betta is best known for developing icotinib, an EGFR-targeted therapy for non-small cell lung cancer and one of China’s landmark domestically developed targeted cancer medicines. Its commercial portfolio has since expanded to include therapies targeting ALK- and EGFR-driven cancers, renal cell carcinoma, and other diseases, while the company continues to advance new targeted therapies and immuno-oncology programs through internal R&D and international partnerships.